Able increasingly un-Able
Executive Summary
President and interim CEO Robert Mauro resigns from Able Labs July 7. Mauro was promoted to succeed former CEO Dhananjay Wadekar, who resigned May 19, as good manufacturing practice concerns forced Able to suspend production of its products and eventually withdraw its NDAs (1"The Pink Sheet" May 30, 2005, p. 23). The firm announced July 8 that it is pursuing a consent decree with FDA and is considering filing for bankruptcy...
You may also be interested in...
Able Labs To Withdraw Seven ANDAs; Data Integrity Concerns Cited
Able Labs "is no longer willing to rely" on the data in some of its approved ANDAs, the generic drug manufacturer said May 23
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.